Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Dhiraj Narula

Clinical Cardiac Electrophysiology Las Vegas, NV Medical Doctor

NPI 1558399485 CMS profile 251686

3131 La Canada St Ste 140, Ste 104, Las Vegas, NV 89169

Open in the dashboard

General payments

$13,721

330 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$49,131 paid to institutions, not to them · program years 2019–2021

Through program year 2025, Dhiraj Narula of Las Vegas, NV is reported in the CMS Open Payments database as having received $13,721 across 330 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $49,131 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 41st percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,057 79
2024 General $3,749 51
2023 General $1,546 46
2022 General $1,944 52
2021 General $1,279 57
2020 General $628 26
2019 General $1,519 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dhiraj Narula
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Dhiraj Narula were reported at $3,057. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Dhiraj Narula Clinical Cardiac Electrophysiology median Middle half National median
2019 $1,519 $2,361 $585–$8,260 $163
2020 $628 $993 $247–$4,351 $114
2021 $1,279 $1,185 $326–$4,739 $132
2022 $1,944 $2,073 $554–$6,789 $149
2023 $1,546 $2,568 $759–$8,159 $160
2024 $3,749 $2,557 $703–$7,403 $164
2025 $3,057 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $2,904 58 payments
  2. Medtronic, Inc. $2,504 50 payments
  3. Abbott Laboratories $2,168 20 payments
  4. Medtronic Vascular, Inc. $1,273 26 payments
  5. Atricure, Inc. $1,067 14 payments
  6. Novartis Pharmaceuticals Corporation $517 24 payments
  7. Merck Sharp & Dohme Corporation $461 22 payments
  8. E.R. Squibb & Sons, L.L.C. $386 25 payments
  9. Janssen Pharmaceuticals, Inc $321 19 payments
  10. Biosense Webster, Inc. $306 5 payments
  11. Other $1,813 67 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,702 313 payments
  2. Travel and Lodging $4,005 16 payments
  3. Education $14 1 payment
Products named General payments · program years 2019–2025
  1. PULSESELECT $1,586 22 payments
  2. AVEIR $1,176 8 payments
  3. EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX $933 13 payments
  4. SelectSecure $533 4 payments
  5. VERQUVO $506 24 payments
  6. FARAPULSE $465 17 payments
  7. Resolute $382 14 payments
  8. ENTRESTO $338 15 payments
  9. XARELTO $321 19 payments
  10. CARDIOMEMS $309 3 payments
  11. Other $5,719 193 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 49 drugs

Part D claims

3,389

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$933,162

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

28.4%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 211 $286,181
Entresto Sacubitril/Valsartan Brand 182 $235,233
Xarelto Rivaroxaban Brand 91 $101,955
Farxiga Dapagliflozin Propanediol Brand 85 $83,894
Dofetilide Generic 321 $59,223
Multaq Dronedarone Hcl Brand 41 $54,015
Jardiance Empagliflozin Brand 33 $37,426
Verquvo Vericiguat Brand 15 $21,941
Brilinta Ticagrelor Brand 12 $8,577
Dabigatran Etexilate Dabigatran Etexilate Mesylate Brand 15 $4,367

The 10 drugs with the highest cost, of 49 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 86 billing codes

Paid by Medicare

$665,162

Of which drugs: $2,167

Medicare patients

627

Average age 77

Services billed

7,461

268 women, 359 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 68%
Ischemic heart disease 53%
Heart failure 52%
Arthritis 45%
Diabetes 43%
Chronic kidney disease 41%
COPD 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 90 360 $2,167

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $87
$87 — —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $83
$83 — —
MULTAQ
  • SANOFI-AVENTIS U.S. LLC $65
$65 41 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $61
$61 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $47
$47 182 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

330 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record